JP7093771B2 - プログラム死１リガンド１（ｐｄ－ｌ１）結合タンパク質及びその使用方法 - Google Patents

プログラム死１リガンド１（ｐｄ－ｌ１）結合タンパク質及びその使用方法 Download PDF

Info

Publication number
JP7093771B2
JP7093771B2 JP2019520935A JP2019520935A JP7093771B2 JP 7093771 B2 JP7093771 B2 JP 7093771B2 JP 2019520935 A JP2019520935 A JP 2019520935A JP 2019520935 A JP2019520935 A JP 2019520935A JP 7093771 B2 JP7093771 B2 JP 7093771B2
Authority
JP
Japan
Prior art keywords
seq
protein
binding protein
heavy chain
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019520935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019525771A5 (enExample
JP2019525771A (ja
Inventor
ラビノビチ，ブライアン
マルティン－オロッコ，ナタリア
ラドヴァニ，ラスズロ
Original Assignee
アイオバンス バイオセラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイオバンス バイオセラピューティクス，インコーポレイテッド filed Critical アイオバンス バイオセラピューティクス，インコーポレイテッド
Publication of JP2019525771A publication Critical patent/JP2019525771A/ja
Publication of JP2019525771A5 publication Critical patent/JP2019525771A5/ja
Application granted granted Critical
Publication of JP7093771B2 publication Critical patent/JP7093771B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019520935A 2016-07-07 2017-07-07 プログラム死１リガンド１（ｐｄ－ｌ１）結合タンパク質及びその使用方法 Active JP7093771B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359612P 2016-07-07 2016-07-07
US62/359,612 2016-07-07
PCT/US2017/041241 WO2018009894A1 (en) 2016-07-07 2017-07-07 Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2019525771A JP2019525771A (ja) 2019-09-12
JP2019525771A5 JP2019525771A5 (enExample) 2020-08-13
JP7093771B2 true JP7093771B2 (ja) 2022-06-30

Family

ID=59366537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520935A Active JP7093771B2 (ja) 2016-07-07 2017-07-07 プログラム死１リガンド１（ｐｄ－ｌ１）結合タンパク質及びその使用方法

Country Status (17)

Country Link
US (2) US11141434B2 (enExample)
EP (1) EP3481867B1 (enExample)
JP (1) JP7093771B2 (enExample)
KR (1) KR102630017B1 (enExample)
CN (1) CN109843921B (enExample)
AU (1) AU2017292889B2 (enExample)
BR (1) BR112019000185A2 (enExample)
CA (1) CA3030156A1 (enExample)
DK (1) DK3481867T3 (enExample)
EA (1) EA201990230A1 (enExample)
ES (1) ES3000676T3 (enExample)
IL (1) IL264104B2 (enExample)
MA (1) MA45595A (enExample)
MX (1) MX2019000149A (enExample)
NZ (1) NZ750005A (enExample)
SG (1) SG11201900138TA (enExample)
WO (1) WO2018009894A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
FI3077041T3 (fi) 2013-12-05 2024-10-16 Rfemb Holdings Llc Syövän immunoterapia radiotaajuisella sähköisellä solukalvon hajotuksella (rf-emb)
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2975123A1 (en) 2015-01-30 2016-08-04 Rfemb Holdings, Llc Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
EP4339287A3 (en) 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
CA3011460A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP4338799A3 (en) * 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
EP3529347A1 (en) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
JP2023507432A (ja) * 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
WO2021222479A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
WO2021222593A2 (en) 2020-04-29 2021-11-04 University Of Southern California Pd-l1 binding peptides
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
EP4572786A1 (en) 2022-08-17 2025-06-25 Purdue Research Foundation Universal natural killer cells derived from human pluripotent stem cells and method of use
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016100985A2 (en) 2014-12-19 2016-06-23 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
EP2316490A3 (en) 2000-10-31 2012-02-01 PR Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
CN101120083B (zh) 2003-10-08 2013-03-27 威尔森沃尔夫制造公司 利用透气性材料进行细胞培养的方法及装置
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CN101104640A (zh) * 2006-07-10 2008-01-16 苏州大学 抗人pd-l1单克隆抗体制备及应用
WO2010036959A2 (en) * 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
WO2010126766A1 (en) 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
WO2011072088A2 (en) 2009-12-08 2011-06-16 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US9315774B2 (en) 2011-10-21 2016-04-19 Cell Medica Limited Device for the aseptic expansion of cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
CN104379727A (zh) 2012-05-18 2015-02-25 威尔逊沃夫制造公司 改进的用于过继细胞治疗的细胞培养方法
CN110241086A (zh) 2012-06-11 2019-09-17 威尔逊沃夫制造公司 用于过继细胞疗法的改进的细胞培养方法
WO2014133567A1 (en) 2013-03-01 2014-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
JP6257655B2 (ja) 2013-03-01 2018-01-10 アメリカ合衆国 末梢血から腫瘍反応性ｔ細胞の濃縮された集団を作製する方法
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
SG10201705494YA (en) 2013-06-24 2017-08-30 Wolf Wilson Mfg Corp Closed system device and methods for gas permeable cell culture process
WO2015039100A1 (en) 2013-09-16 2015-03-19 The Trustees Of The University Of Pennsylvania Cd137 enrichment for efficient tumor infiltrating lymphocyte selection
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
EP3698850A1 (en) 2014-03-20 2020-08-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
ES2980788T3 (es) 2014-04-10 2024-10-03 H Lee Moffitt Cancer Ct & Res Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva
UA123821C2 (uk) 2014-06-11 2021-06-09 Полібіосепт Гмбх Композиція для експансії лімфоцитів in vitro
KR20250007689A (ko) * 2014-09-16 2025-01-14 이나뜨 파르마 에스.에이. 림프구에서의 억제 경로의 중화
ES2924709T3 (es) 2014-10-02 2022-10-10 Us Health Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
CN110099998A (zh) 2016-10-26 2019-08-06 艾欧凡斯生物治疗公司 冷冻保存的肿瘤浸润淋巴细胞的再刺激
AU2018205234B2 (en) 2017-01-06 2024-09-19 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
WO2018209115A1 (en) 2017-05-10 2018-11-15 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
TW201919662A (zh) 2017-06-05 2019-06-01 美商艾歐凡斯生物治療公司 對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016100985A2 (en) 2014-12-19 2016-06-23 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Eloah Rabello Suarez et al.，Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.，Oncotarget，7，2016年04月29日，34341-34355

Also Published As

Publication number Publication date
US20190298770A1 (en) 2019-10-03
CA3030156A1 (en) 2018-01-11
MX2019000149A (es) 2019-09-23
EP3481867A1 (en) 2019-05-15
AU2017292889A1 (en) 2019-02-14
US12023355B2 (en) 2024-07-02
BR112019000185A2 (pt) 2019-04-16
JP2019525771A (ja) 2019-09-12
IL264104B2 (en) 2024-08-01
CN109843921A (zh) 2019-06-04
ES3000676T3 (en) 2025-03-03
EA201990230A1 (ru) 2019-07-31
US11141434B2 (en) 2021-10-12
SG11201900138TA (en) 2019-02-27
US20220025052A1 (en) 2022-01-27
MA45595A (fr) 2019-05-15
IL264104A (en) 2019-01-31
AU2017292889B2 (en) 2024-09-12
CN109843921B (zh) 2023-05-26
IL264104B1 (en) 2024-04-01
EP3481867B1 (en) 2024-09-04
WO2018009894A1 (en) 2018-01-11
KR20190038825A (ko) 2019-04-09
KR102630017B1 (ko) 2024-01-25
NZ750005A (en) 2023-06-30
DK3481867T3 (da) 2024-11-11

Similar Documents

Publication Publication Date Title
US12023355B2 (en) Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof
TWI840351B (zh) T細胞受體及表現其之工程化細胞
JP7034934B2 (ja) キメラ抗原及びｔ細胞受容体、並びに使用方法
JP2026021445A (ja) 合成免疫受容体およびその使用方法
JP6865688B2 (ja) Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
JP2022523781A (ja) Ｄｌｌ３標的化キメラ抗原受容体および結合剤
KR20210057705A (ko) 세포 요법을 위한 다양한 항원 결합 도메인, 신규한 플랫폼 및 다른 향상
JP2019083821A (ja) タグ化キメラエフェクター分子およびそのレセプター
KR20190003938A (ko) 면역치료를 위한 변형된 세포
EP4117716B1 (en) Methods for generating engineered memory-like nk cells and compositions thereof
US20200262894A1 (en) Strep-tag specific binding proteins and uses thereof
KR20230012465A (ko) 암 및 관련 악성 종양을 치료하기 위해 t 세포를 확장하는 방법
US20260124303A1 (en) Fibroblast activation protein (fap) car-invariant natural killer t cells and uses thereof
JP2023500318A (ja) 細胞選択および／または細胞刺激デバイスならびに使用方法
JP2024510184A (ja) 治療用ｔ細胞毒性を減少させるための組成物および方法
CN112041432A (zh) Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
CN120152735A (zh) Adgre2嵌合受体nk细胞组合物和使用方法
HK40009925A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
HK40008962A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
HK40008962B (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
HK40009925B (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
EA040856B1 (ru) Белки, связывающие лиганд 1 запрограммированной смерти 1 (pd-l1), и способы их использования
CN117295506A (zh) 降低治疗性t细胞毒性的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200703

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220218

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220218

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220301

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220419

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220523

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220620

R150 Certificate of patent or registration of utility model

Ref document number: 7093771

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250